Coding Guidelines BONES, JOINTS, AND ARTICULAR CARTILAGE C400–C419 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM C470–C479 CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES C490–C499

(Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Laterality

Laterality is required for sites C400-C403, C413-C414, C471-C472, and C491-C492.

Three Grade System (Nuclear Grade)

There are several sites for which a three-grade system is used. The patterns of cell growth are measured on a scale of 1, 2, and 3 (also referred to as low, medium, and high grade). This system measures the proportion of cancer cells that are growing and making new cells and how closely they resemble the cells of the host tissue. Thus, it is similar to a four-grade system, but simply divides the spectrum into three rather than four categories (see comparison table below). The expected outcome is more favorable for lower grades. Soft tissue sarcomas are evaluated using a three-grade system.

If a grade is written as 2/3 that means this is a grade 2 of a three-grade system. Do not simply code the numerator. Use the following table to convert the grade to SEER codes.

Term	Grade	SEER Code
1/3, 1/2	Low grade	2
2/3	Intermediate grade	3
3/3, 2/2	High grade	4

Sarcoma

Sarcomas are graded low, intermediate or high grade by the pathologist. Use the following table to convert these terms to a histologic grade.

Term	Grade	SEER Code
Well differentiated	Ι	1
Fairly well differentiated	Π	2
Low grade	I-II	2
Mid differentiated	Π	2
Moderately differentiated	Π	2
Partially differentiated	Π	2
Partially well differentiated	I-II	2
Partially well differentiated	Π	2
Relatively or generally well differentiated	Π	2
Medium grade, intermediate grade	II-III	3
Moderately poorly differentiated	III	3
Moderately undifferentiated	III	3
Poorly differentiated	III	3
Relatively poorly differentiated	III	3
Relatively undifferentiated	III	3
Slightly differentiated	III	3
High grade	III-IV	4
Undifferentiated, anaplastic, not differentiated	IV	4

Bones, Joints, Cartilage C400-C419

Note: For Multiple Primary and Histology Coding Rules: see Other Sites (pg C-1079)

CS Staging Schemas

Bone

C40.0-C40.3, C40.8-C40.9, C41.0-C41.4, C41.8-C41.9

C40.0 Long bones of upper limb, scapula and associated joints C40.1 Short bones of upper limb and associated joints C40.2 Long bones of lower limb and associated joints C40.3 Short bones of lower limb and associated joints C40.8 Overlapping lesion of bones, joints and articular cartilage of limbs C40.9 Bone of limb, NOS C41.0 Bones of skull and face and associated joints (excludes mandible C41.1) C41.1 Mandible C41.2 Vertebral column (excludes sacrum and coccyx C41.4) C41.3 Rib, sternum, clavicle and associated joints C41.4 Pelvic bones, sacrum, coccyx and associated joints C41.8 Overlapping lesion of bones, joints and articular cartilage C41.9 Bone, NOS Note: Laterality must be coded for C40.0-C40.3, and C41.3-C41.4. For sternum, sacrum, coccyx, and symphysis

pubis, laterality is coded 0.

CS Tumor Size CS Extension CS TS/Ext-Eval CS Lymph Nodes CS Reg Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval

CS Site-Specific Factor 1 CS Site-Specific Factor 2 CS Site-Specific Factor 3 CS Site-Specific Factor 4 CS Site-Specific Factor 5 CS Site-Specific Factor 6

The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage **Extension Size Table**

Bone

CS Tumor Size SEE STANDARD TABLE

Bone

CS Extension (Revised: 12/05/2003)

Note: The cortex of a bone is the dense outer shell that provides strength to the bone; the spongy center of a bone is the cancellous portion. The periosteum of the bone is the fibrous membrane covering of a bone that contains the blood vessels and nerves; the periosteum is similar to the capsule on a visceral organ.

Code	Description	TNM	SS77	SS2000
10	Invasive tumor confined to cortex of bone	*	L	L
20	Extension beyond cortex to periosteum (no break in periosteum)	*	L	L
30	Localized, NOS	*	L	L
40	Extension beyond periosteum to surrounding tissues, including adjacent skeletal muscle(s)	*	RE	RE
60	Adjacent bone/cartilage	*	RE	RE
70	Skin	*	D	D
80	Further contiguous extension	*	D	D
82	Skip metastases or discontinuous tumors in the same bone	Т3	D	D
95	No evidence of primary tumor	T0	U	U

CS Staging Schemas

99	Unknown extension	ТХ	U	U
	Primary tumor cannot be assessed			
	Not documented in patient record			

* For codes 10, 20, 30, 40, 60, 70, and 80 ONLY, the T category is assigned based on the value of CS Tumor Size, as shown in the Extension Size Table for this site.

Bone CS TS/Ext-Eval SEE STANDARD TABLE

Bone

CS Lymph Nodes (Revised: 03/17/2004)

Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX. **Note 2:** Regional lymph nodes are defined as those in the vicinity of the primary tumor.

Note 3: Regional lymph node involvement is rare. If there is no mention of lymph node involvement clinically, assume that lymph nodes are negative.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Regional lymph nodes	N1	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NX	U	U

Bone CS Reg Nodes Eval SEE STANDARD TABLE

Bone Reg LN Pos SEE STANDARD TABLE

Bone Reg LN Exam SEE STANDARD TABLE

CS Staging Schemas

Bone CS Mets at DX (Revised: 12/05/2003)

Code	Description	TNM	SS77	SS2000
00	No; None	M0	NONE	NONE
10	Distant lymph node(s)	M1b	D	D
30	Distant metastasis to lung only	M1a	D	D
40	Distant metastases except distant lymph node(s) or lung Distant metastasis, NOS Carcinomatosis	M1b	D	D
50	(10) + ((30) + 40)) Distant lymph node(s) plus other distant metastases	M1b	D	D
55	Stated as M1 NOS	M1NOS	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Bone CS Mets Eval SEE STANDARD TABLE

Bone

CS Site-Specific Factor 1 (Revised: 03/27/2003)

Code	Description
888	Not applicable for this site

Bone

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Bone

CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

CS Staging Schemas

Bone CS Site-Specific Factor 4 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Bone CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Bone

CS Site-Specific Factor 6 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Surgery Codes

Bones, Joints, And Articular Cartilage C400–C419 Peripheral Nerves And Autonomic Nervous System C470–C479 Connective, Subcutaneous, And Other Soft Tissues C490–C499 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS
- Unknown whether a specimen was sent to pathology for surgical events coded 19 (Principally for cases diagnosed prior to January 1, 2003)
- 15 Local tumor destruction

No specimen sent to pathology from surgical event 15

- 25 Local excision
- 26 Partial resection

Specimen sent to pathology from surgical events 25–26

- 30 Radical excision or resection of lesion WITH limb salvage
- 40 Amputation of limb
 - 41 Partial amputation of limb
 - 42 Total amputation of limb

50 Major amputation, NOS

- 51 Forequarter, including scapula
- 52 Hindquarter, including ilium/hip bone
- 53 Hemipelvectomy, NOS
- 54 Internal hemipelvectomy
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

Non-Melanoma Skin C440-C449

Note: For Multiple Primary and Histology Coding Rules: see Other Sites (pg C-1079)

CS Staging Schemas

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] C44.0, C44.2-C44.9

C44.0 Skin of lip, NOS C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb and shoulder C44.7 Skin of lower limb and hip C44.8 Overlapping lesion of skin C44.9 Skin, NOS **Note:** Laterality must be coded for C44.2-C44.3 and C44.5-C44.7. For codes C44.3 and C44.5, if the tumor is midline (e.g., chin), code as 9, midline, in the laterality field.

CS Tumor Size CS Extension CS TS/Ext-Eval CS Lymph Nodes CS Reg Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval	CS Site-Specific Factor 1 CS Site-Specific Factor 2 CS Site-Specific Factor 3 CS Site-Specific Factor 4 CS Site-Specific Factor 5 CS Site-Specific Factor 6	The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage Extension Size Table
CS Mets Eval		

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Tumor Size SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Extension (Revised: 12/10/2003)

Note 1: In the case of multiple simultaneous tumors, code the tumor with greatest extension.

Note 2: Skin ulceration does not alter the Collaborative Stage classification.

Note 3: Skin of genital sites is not included in this schema. These sites are skin of vulva (C51.0-C51.2, C51.8-C51.9), skin of penis (C60.0-C60.1, C60.8, C60.9) and skin of scrotum (C63.2).

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; intraepidermal; Bowen disease	Tis	IS	IS
10	Lesion(s) confined to dermis	*	L	L
40	Localized, NOS	*	L	L
50	Subcutaneous tissue (through entire dermis)	*	L	L
70	Underlying cartilage, bone, skeletal muscle	T4	D	RE
80	Further contiguous extension	T4	D	D
95	No evidence of primary tumor	TO	U	U

CS Staging Schemas

99	Unknown extension	TX	U	U
	Primary tumor cannot be assessed			
	Not documented in patient record			

* For Extension codes 10, 40 and 50 ONLY, the T category is assigned based on value of CS Tumor Size from Extension Size Table for this site.

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS TS/Ext-Eval SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Lymph Nodes (Revised: 08/15/2006)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code Description	TNM	SS77	SS2000
00 None; no regional lymph node involvement	NO	NONE	NONE
10 Regional lymph nodes by primary site (includes bilateral or contralateral nodes for head, neck, and trunk) 11 Regional lymph nodes by primary site (includes bilateral or contralateral nodes for head, neck, and trunk) 11 HEAD AND NECK: 11 All subsites: Cervical 12 Lip: 12 Mandibular, NOS: 13 Submandibular (submaxillary) 14 External ear/auditory canal: 15 Mastoid (post-/retro-auricular) (occipital) 16 Preauricular 17 Face, Other (cheek, chin, forehead, jaw, nose and temple): 18 Facial, NOS: 19 Buccinator (buccal) 10 Nasolabial 11 Mandibular, NOS: 11 Submandibular (submaxillary) 11 Parotid, NOS: 11 Infra-auricular 11 Preauricular 11 Parotid, NOS: 11 Infra-auricular 10 Parotid, NOS: 11 Infra-auricular 11 Preauricular 12 Spinal accessory (posterior cervical) 12 Neck:	N1	RN	RN

CS Staging Schemas

10, cont'd	UPPER TRUNK: Axillary Cervical Internal mammary (parasternal)			
	Supraclavicular (transverse cervical) LOWER TRUNK: Femoral (superficial inguinal) ARM/SHOULDER: Axillary Epitrochlear for hand/forearm Spinal accessory for shoulder LEG/HIP: Femoral (superficial inguinal) Popliteal for heel and calf			
	ALL SITES: Regional lymph node(s), NOS			
20	HEAD AND NECK: Lip: Facial, NOS: Buccinator (buccal) Nasolabial Submental Parotid, NOS: Infra-auricular Preauricular Face, Other (cheek, chin, forehead, jaw, nose, and temple): Submental Neck: Submental	N1	D	RN
30	(10) + (20)	N1	D	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph nodes cannot be assessed Not documented in patient record	NX	U	U

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Reg Nodes Eval SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] Reg LN Pos SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] Reg LN Exam SEE STANDARD TABLE

CS Staging Schemas

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Mets at DX SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Mets Eval SEE STANDARD TABLE

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Site-Specific Factor 1 (Revised: 03/27/2003)

	Scenic 1 actor 1 (Revised: 05/2/12003)
Code	Description
888	Not applicable for this site

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 4 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas]

CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

CS Staging Schemas

Skin [excl. Skin of Eyelid] [excl. Malignant Melanoma, Kaposi Sarcoma, Mycosis Fungoides, Sezary Disease, and Other Lymphomas] CS Site-Specific Factor 6 (Revised: 03/31/2002)

 Code
 Description

 888
 Not applicable for this site

CS Staging Schemas

Skin of Eyelid C44.1 C44.1 Eyelid Note: Laterality must be coded for this site.

- CS Tumor Size CS Extension CS TS/Ext-Eval CS Lymph Nodes CS Reg Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval
- CS Site-Specific Factor 1 CS Site-Specific Factor 2 CS Site-Specific Factor 3 CS Site-Specific Factor 4 CS Site-Specific Factor 5 CS Site-Specific Factor 6

The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage for TNM sites with no stage groupings Extension Size Table

Skin of Eyelid CS Tumor Size SEE STANDARD TABLE

Skin of Eyelid

CS Extension (Revised: 08/18/2006)

Note 1: In the case of multiple simultaneous tumors, code the tumor with greatest extension.

Note 2: Skin ulceration does not alter the Collaborative Stage classification.

Note 3: Presence of tumor at eyelid margin takes priority over depth of invasion in dermis/tarsal plate; i.e., code 25 takes priority over codes 10-20.

Code	Description	TNM	SS77	SS2000
00	In situ; noninvasive; intraepithelial Bowen disease; intraepidermal	Tis	IS	IS
10	Lesion(s) confined to dermis Minimal infiltration of dermis (not invading tarsal plate)	T1	L	L
20	Infiltrates deeply into dermis (invading tarsal plate)	T2	L	L
25	Tumor at eyelid margin	*	L	L
30	Involves full eyelid thickness	Т3	L	L
40	Localized, NOS	T1	L	L
50	Subcutaneous tissue (through entire dermis)	Т3	L	L
60	Adjacent structures, including: Bulbar conjunctiva Globe Perineural space Sclera Soft tissues of orbit	T4	D	RE
70	Bone/periosteum of orbit Skeletal muscle Underlying cartilage	T4	D	RE

CS Staging Schemas

72	Nasal cavity Paranasal sinuses	T4	D	D
74	Central nervous system	T4	D	D
75	Metastatic skin lesion(s)	T4	D	D
80	Further contiguous extension	T4	D	D
95	No evidence of primary tumor	TO	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For Extension code 25 ONLY, the T category is assigned based on value of CS Tumor Size as shown in Extension Size Table. Tumors 5mm or less are T1, tumors 6-10mm are T2, and tumors more than 10mm are T3.

Skin of Eyelid CS TS/Ext-Eval SEE STANDARD TABLE

Skin of Eyelid CS Lymph Nodes (Revised: 04/12/2004)

Note: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Regional lymph node(s) Cervical, NOS Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Submental Parotid, NOS: Infra-auricular Preauricular Regional lymph node(s), NOS	N1	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

Skin of Eyelid CS Reg Nodes Eval SEE STANDARD TABLE

Skin of Eyelid Reg LN Pos SEE STANDARD TABLE

Skin of Eyelid Reg LN Exam SEE STANDARD TABLE

CS Staging Schemas

Skin of Eyelid CS Mets at DX SEE STANDARD TABLE

Skin of Eyelid CS Mets Eval SEE STANDARD TABLE

Skin of Eyelid CS Site-Specific Factor 1 (Revised: 03/27/2003)

Code	Description
888	Not applicable for this site

Skin of Eyelid

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin of Eyelid

CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin of Eyelid CS Site-Specific Factor 4 (Revised: 03/31/2002)

ſ	Code	Description
	888	Not applicable for this site

Skin of Eyelid

CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Skin of Eyelid

CS Site-Specific Factor 6 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Surgery Codes

Skin C440–C449 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[SEER Note: Codes 21 to 24 above combine 20 Local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

[*SEER Notes:* Code UVB phototherapy for mycosis fungoides primaries under Surgery of Primary Site for skin. Assign code 11 if there is no pathology specimen. Assign code 21 if there is a pathology specimen. Codes 20-27 include shave and wedge resection]

- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
 - 31 Shave biopsy followed by a gross excision of the lesion
 - 32 Punch biopsy followed by a gross excision of the lesion
 - 33 Incisional biopsy followed by a gross excision of the lesion
 - 34 Mohs surgery, NOS
 - 35 Mohs with 1-cm margin or less
 - 36 Mohs with more than 1-cm margin

[*SEER Notes:* Codes 30 to 33 include less than a wide excision, less than 1 cm margin or margins are unknown. If it is stated to be a **wide excision** or **reexcision**, but the **margins are unknown**, code to 30. Code 45 represents a wide excision in which it is known that the margins of excision are greater than 1 cm.]

Surgery Codes

- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. Margins MUST be microscopically negative.
 - 46 WITH margins more than 1 cm and less than or equal to 2 cm
 - 47 WITH margins greater than 2 cm

If the excision does not have microscopically negative margins greater than 1 cm, use the appropriate code, 20-36.

- 60 Major amputation
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

Melanoma M8720-8790

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Introduction

Cutaneous melanoma starts in the melanocyte cells of the skin. Melanocytes lie in the epidermis, the outermost layer of the skin. Melanocytes often cluster together and form moles (nevi). Most moles are benign, but some may go on to become malignant melanomas.

Melanomas are divided into 5 main types, depending on their location, shape and whether they grow outward or downward into the dermis:

- Acral melanoma: occurs on the palms of the hand, soles of the feet, or nail beds
- Desmoplastic melanoma: is a rare malignant melanoma marked by non-pigmented lesions on sun-exposed areas of the body
- Lentigo maligna: usually occur on the faces of elderly people
- Superficial spreading or flat melanoma: grows outwards at first to form an irregular pattern on the skin with an uneven color
- Nodular melanomas: are lumpy and often blue-black in color and may grow faster and spread downwards

These types account for the majority of melanomas occurring in the US population. For a more complete listing of histologic types of melanoma, see the *AJCC Cancer Staging Manual*, 6th Ed.

Melanoma can also start in the mucous membranes of the mouth, anus and vagina, in the eye or other places in the body where melanocytes are found. This scheme is used only for melanomas that occur on the skin.

Equivalent or Equal Terms

- Tumor, mass, lesion, neoplasm
- Type, subtype, predominantly, with features of, major, or with <u>differentiation</u>.
- Giant pigmented nevus, giant congenital nevus
- Mole, Nevus

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Synonyms for In Situ

Behavior code 2 Clark level 1 (limited to the epithelium) Hutchinson freckle (See synonyms for Hutchinson freckle) Intraepidermal, NOS Intraepithelial, NOS Lentigo maligna Noninvasive Precancerous melanoma of Dubreuilh Stage 0 Tis

Synonyms for Hutchinson freckle

Circumscribed precancerous melanosis Intraepidermal malignant melanoma Lentigo maligna Precancerous melanosis of Dubreuilh

Definitions

Amelanotic melanoma: A non-pigmented malignant melanoma.

Atypical melanocytic hyperplasia (dysplasia): Tumor-like lesion or condition may represent precursor stage or stage in development of melanoma. Not reportable.

Different lateralities: The right side of the body, the left side of the body and the midline are separate lateralities in the melanoma coding rules.

Evolving melanoma (borderline evolving melanoma): Evolving melanoma are tumors of uncertain biologic behavior. Histological changes of borderline evolving melanoma are too subtle for a definitive diagnosis of melanoma in situ. The tumors may be described as "proliferation of atypical melanocytes confined to epidermal and adnexal epithelium," "atypical intraepidermal melanocytic proliferation, "atypical intraepidermal melanocytic hyperplasia"; or "severe melanocytic dysplasia." Not reportable.

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Familial Atypical Multiple Mole Melanoma Syndrome (FAMM, FAM-M): An inherited condition identified when:

- Melanoma has been diagnosed in a family member, including grandparents, aunts, uncles, and cousins
- Several family members have large numbers of moles (often more than 50) which may be abnormal or atypical moles.

Giant pigmented nevus: Diameter larger than 20 cm; frequently covers large areas of the body in a garment-like fashion. The trunk, head and neck are the most common sites.

Junctional nevus: Smooth, hairless, light to dark brown mole. Can be slightly elevated, usually multiple and can occur on any part of the body. Melanocytes are confined to the dermo-epidermal junction.

Hypodermis: A subcutaneous layer of loose connective tissue containing a varying number of fat cells. Synonyms: subcutaneous fat; subcutis.

In-transit metastasis: Metastasis found in the lymphatic channels more than 2cm away from the primary melanoma, but not reaching the regional lymph nodes.

Invasive tumor: A tumor that penetrates the basement membrane and invades the dermis.

Laterality: For skin sites, laterality divides the body into a right and left half as though a line were drawn from mid forehead to mid pelvis and from mid skull to mid buttocks. A midline laterality describes a tumor that is in the center of the "line" drawn from the mid forehead to mid pelvis or from the mid skull to the mid buttocks; it is impossible to categorize the tumor as being on the right or left side of the body.

SEER Program Coding and Staging Manual 2007

Lentigo maligna: Is a specific histologic type of in situ melanoma. It appears as a brown or black mottled, irregular, lesion with increased numbers of scattered atypical melanocytes in the epidermis. It usually occurs on the face.

Lentigo maligna melanoma: Is an invasive melanoma that begins as lentigo maligna, but usually after many years the dermis is invaded by the tumor. Once invasion has occurred, the lesion is called lentigo maligna **melanoma**.

Midline: the middle dividing line that separates the body into right and left sides.

Most invasive: the histology that has the greatest extension into the dermis or subcutaneous fat.

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Non-invasive tumor: A tumor confined to epithelium (intraepithelial), in situ tumor, with no penetration below the basement membrane.

Precancerous melanosis: An obsolete term for lentigo maligna.

Proliferation of atypical melanocytes confined to epidermis: Number of (proliferation) pigmented cells (melanocytes) not showing the normal cell structure (atypical). Not reportable.

Regressing melanoma: The term "regressing melanoma" does not refer to a specific histology; it refers to the physical appearance and size of the lesion. A regressing melanoma is reacting to the body's immune system by shrinking in size. Partial spontaneous regression is not an uncommon finding in invasive primary melanoma; partial regression can be an indicator of poor prognosis. Proven complete regression is very rare; one website stated that only 33 cases of total regression have been reported. A regressive melanoma is usually thinner than it was originally. Although regression is a prognostic factor, the histologic type is more important for histology coding purposes. See Histology coding rules, Rule H5.

Satellite lesion or metastasis: Grossly evident metastatic skin lesion within the immediate vicinity (usually within 2 cm) of a primary malignant tumor; e.g., skin adjacent to primary malignant melanoma. This is a metastasis, not a separate primary.


Severe melanotic dysplasia: Tumor-like lesion or condition. Not reportable.

Skin Layers:

- Epidermis upper surface, thin layer (outermost layer)
- Dermis lower, intermediate thicker layer (intermediate layer)
- Hypodermis also called subcutis or subcutaneous fat lowest layer (innermost layer)

Site-Specific Coding Modules

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)




SEER Program Coding and Staging Manual 2007

Image from LUMEN - Loyola University Medical Education Network, used with permission.

All rights reserved.

Equivalent Terms, Definitions and Illustrations C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Anatomy of Normal Skin



Source: Burnsurgery.org Image used with permission. All rights reserved.


Multiple Primary Rules – Flowchart


Cutaneous Melanoma Multiple Primary Rules - Flow chart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. **

Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.






Multiple Primary Rules – Flowchart

Cutaneous Melanoma Multiple Primary Rules - Flowchart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site) Flowchart Key destan

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.



Multiple Primary Rules – Flowchart

Flowchart Key

cisio

Flow Directio


Nate

Cutaneous Melanoma Multiple Primary Rules - Flow chart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)

Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.




Histology Coding Rules – Flowchart

Cutaneous Melanoma Histology Coding Rules - Flowchart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)






Histology Coding Rules – Flowchart

Cutaneous Melanoma Histology Coding Rules - Flowchart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)







Histology Coding Rules – Flowchart

Cutaneous Melanoma Histology Coding Rules - Flowchart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)





Histology Coding Rules – Flowchart


Cutaneous Melanoma Histology Coding Rules - Flowchart

(C440 - C449 with Histology 8720 - 8780) (Excludes melanoma of any other site)



SEER Program Coding and Staging Manual 2007

SINGLE MELANOMA OR MULTIPLE MELANOMAS ABSTRACTED AS A SINGLE PRIMARY



This is the end of instructions for Single Melanoma or Multiple Melanomas Abstracted as a Single Primary. Code the histology according to the rule that fits the case.

Multiple Primary Rules - Matrix C440 – C449 (Excludes melanoma of any other site)

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.

** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.

Rule	Site	Histology	Timing	Behavior	Notes/Examples	Primary	
UNKN	NOWN IF SINGLE OR M	IULTIPLE MELANOM	AS		Melanoma(s) not described as metastasis		
M1					Use this rule only after all information sources have been exhausted.	Single*	
SING	LE MELANOMA				1: Melanoma not described as metastas		
			r		2: Includes combinations of in situ and	1	
M2	Single					Single*	
MUL	FIPLE MELANOMAS				1: Melanoma not described as metastas		
Multip	le melanomas may be a sing	le primary or multiple prin	naries		2: Includes combinations of in situ and	invasive	
M3	Topography codes are different at the second $(C\underline{x}xx)$, third $(Cx\underline{x}x)$ or fourth $(Cxxx)$ character					Multiple**	
M4	Different laterality				 A midline melanoma is a different laterality than right or left. <i>Example 1:</i> A melanoma on the right side of the chest and a melanoma at midline on the chest are different laterality, multiple primaries. <i>Example 2:</i> A melanoma on the right side of the chest and a melanoma on the left side of the chest are multiple primaries. 	Multiple**	
M5		Histology codes are different at the first (<u>x</u> xxx), second (x <u>x</u> xx), or third (xx <u>x</u> x) number				Multiple**	

SEER Program Coding and Staging Manual 2007

Multiple Primary Rules - Matrix
C440 – C449 (Excludes melanoma of any other site)

Rule	Site	Histology	Timing	Behavior	Notes/Examples	Primary
M6			More than 60 days after diagnosis	An invasive melanoma following an in situ melanoma	 <i>I:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease. 	Multiple**
M7			Diagnosed more than 60 days apart			Multiple**
M8	Does not meet any	of the above criteria			 <i>I:</i> Use the data item "Multiplicity Counter" to record the number of melanomas abstracted as a single primary. <i>2:</i> When an invasive melanoma follows an in situ melanoma within 60 days, abstract as a single primary. <i>3:</i> All cases covered by this rule are the same site and histology. Rule M8 Examples The following are examples of the types of cases that use Rule M8. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary. <i>Warning: Using only these case examples to determine the number of primaries can result in major errors.</i> Example 1: Solitary melanoma on the left back and another solitary melanoma on the left chest Example 2: Solitary melanoma on the right thigh and another solitary melanoma on the right ankle 	Single*

Histology Coding Rules - Matrix C440-C449 (Excludes melanoma of all other sites)

Rule	Melanoma Specimen	Histology	Behavior	Notes and Examples	Code		
SING	SINGLE MELANOMA OR MULTIPLE MELANOMAS ABSTRACTED AS A SINGLE PRIMARY						
H1	No pathology/cytology specimen or the pathology/cytology report is not available			 <i>I</i>: Priority for using documents to code the histology Documentation in the medical record that refers to pathologic or cytologic findings Physician's reference to type of melanoma in the medical record PET scan <i>2</i>: Code the specific histology when documented. 	The histology documented by the physician		
H2	None from primary site			Code the behavior /3	The histology from metastatic site		
H3		One type			The histology		
H4			Invasive and in situ		The invasive histologic type		
Н5		Regressing melanoma and a histologic type		<i>Example:</i> Nodular melanoma with features of regression. Code 8721 (Nodular melanoma).	The histologic type		
H6		Regressing melanoma		<i>Example:</i> Malignant melanoma with features of regression. Code 8723.	8723 (Malignant melanoma, regressing)		
H7		Lentigo maligna melanoma and a histologic type			The histologic type		
H8		Lentigo maligna melanoma			8742 (Lentigo maligna melanoma)		

Histology Coding Rules - Matrix C440-C449 (Excludes melanoma of all other sites)

Rule	Melanoma Specimen	Histology	Behavior	Notes and Examples	Code
H9		Melanoma, NOS (8720) with a single specific type		 The specific type for in situ lesions may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or withdifferentiation. The specific type for invasive lesions may be identified as type, subtype, predominantly, with features of, major, or withdifferentiation. 	The most specific histologic term
H10	None of the above conditions ar	re met			The histology with the numerically higher ICD-O-3 code

Multiple Primary Rules – Text C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

UNKNOWN IF SINGLE OR MULTIPLE MELANOMAS

Note: Melanoma(s) not described as metastasis

Rule M1 When it is not possible to determine if there is a single melanoma or multiple melanomas, opt for a single melanoma and abstract as a single primary.* *Note:* Use this rule only after all information sources have been exhausted

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. This is the end of instructions for Unknown if Single or Multiple Melanoma.

SINGLE MELANOMA

Note 1: Melanoma not described as metastasis *Note 2:* Includes combinations of in situ and invasive

Rule M2 A single melanoma is always a single primary. *

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. This is the end of instructions for Single Melanoma.

MULTIPLE MELANOMAS

Multiple melanomas may be a single primary or multiple primaries *Note 1:* Melanoma not described as metastases *Note 2:* Includes combinations of in situ and invasive

Rule M3 Melanomas in sites with ICD-O-3 **topography** codes that are **different** at the second ($C\underline{x}xx$), third ($Cx\underline{x}x$) or fourth (C44 \underline{x}) character are multiple primaries. **

Appendix C

Multiple Primary Rules – Text C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Rule M4	Melanomas with different laterality are multiple primaries. **
	<i>Note:</i> A midline melanoma is a different laterality than right or left.
	Example 1: Melanoma of the right side of the chest and a melanoma at midline of the chest are different laterality, multiple primaries Example 2: A melanoma of the right side of the chest and a melanoma of the left side of the chest are multiple primaries
Rule M5	Melanomas with ICD-O-3 histology codes that are different at the first ($\underline{\mathbf{x}}$ xxx), second ($x\underline{\mathbf{x}}$ xx) or third number (xxxx) are multiple primaries. **
Rule M6	An invasive melanoma that occurs more than 60 days after an in situ melanoma is a multiple primary. ** <i>Note 1:</i> The purpose of this rule is to ensure that the case is counted as an incident (invasive) case when incidence data are analyzed. <i>Note 2:</i> Abstract as multiple primaries even if the medical record/physician states it is recurrence or progression of disease.
Rule M7	Melanomas diagnosed more than 60 days apart are multiple primaries. **
Rule M8	Melanomas that do not meet any of the above criteria are abstracted as a single primary. * <i>Note 1:</i> Use the data item "Multiplicity Counter" to record the number of melanomas abstracted as a single primary. <i>Note 2:</i> When an invasive melanoma follows an in situ melanoma within 60 days, abstract as a single primary. <i>Note 3:</i> All cases covered by this rule are the same site and histology.

* Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. ** Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted. This is the end of instructions for Multiple Melanomas.

Rule M8 Examples: The following are examples of cases that use Rule M8. This is NOT intended to be an exhaustive set of examples; there are other cases that may be classified as a single primary. *Warning: Using only these case examples to determine the number of primaries can result in major errors.*

Example 1: Solitary melanoma on the left back and another solitary	Example 2: Solitary melanoma on the right thigh and another solitary
melanoma on the left chest.	melanoma on the right ankle.

Histology Coding Rules – Text C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

Rule H1	Code the histology documented by the physician when there is no pathology/cytology specimen or the pathology/cytology report is not available .
	<i>Note 1:</i> Priority for using documents to code the histology
	 Documentation in the medical record that refers to pathologic or cytologic findings
	Physician's reference to type of melanoma in the medical record
	• PET scan
	<i>Note 2:</i> Code the specific histology when documented.
Rule H2	Code the histology from the metastatic site when there is no pathology/cytology specimen from the primary site . <i>Note:</i> Code the behavior /3.
Rule H3	Code the histology when only one histologic type is identified.
Rule H4	Code the invasive histologic type when there are invasive and in situ components.
Rule H5	Code the histologic type when the diagnosis is regressing melanoma and a histologic type. <i>Example:</i> Nodular melanoma with features of regression. Code 8721 (Nodular melanoma).
Rule H6	Code 8723 (Malignant melanoma, regressing) when the diagnosis is regressing melanoma . <i>Example</i> : Malignant melanoma with features of regression. Code 8723.
Rule H7	Code the histologic type when the diagnosis is lentigo maligna melanoma and a histologic type.
Rule H8	Code 8742 (Lentigo maligna melanoma) when the diagnosis is lentigo maligna melanoma.

Histology Coding Rules – Text C440-C449 with Histology 8720-8780 (Excludes melanoma of any other site)

 Rule H9
 Code the most specific histologic term when the diagnosis is melanoma, NOS (8720) with a single specific type.

 Note 1: The specific type for in situ lesions may be identified as pattern, architecture, type, subtype, predominantly, with features of, major, or with ______differentiation

 Note 2: The specific type for invasive lesions may be identified as type, subtype, predominantly, with features of, major, or with ______differentiation.

Rule H10 Code the histology with the **numerically higher** ICD-O-3 code.

This is the end of instructions for Single Melanoma or Multiple Melanomas Abstracted as a Single Primary. Code the histology according to the rule that fits the case.

CS Staging Schemas

Malignant Melanoma of Skin, Vulva, Penis, Scrotum C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 (M-8720-8790) C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear

C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb and shoulder C44.7 Skin of lower limb and hip C44.8 Overlapping lesion of skin C44.9 Skin, NOS C51.0 Labium majus C51.1 Labium minus C51.2 Clitoris C51.8 Overlapping lesion of vulva C51.9 Vulva, NOS C60.0 Prepuce C60.1 Glans penis C60.2 Body of penis C60.8 Overlapping lesion of penis C60.9 Penis C63.2 Scrotum, NOS

Note 1: Laterality must be coded for C44.1-C44.3, and C44.5-C44.7. For codes C44.3 and C44.5, if the tumor is midline (e.g., chin), code as 9, midline, in the laterality field.

Note 2: For melanoma of sites other than those above, use the site-specific schema for the appropriate site. **Note 3:** The level of invasion, as defined by Dr. Wallace Clark, is used when defining subcategories of T1 melanomas, but not for thicker melanoma (i.e, T2, T3 or T4).

CS Tumor Size	CS Site-Specific Factor 1 -	The following tables are
CS Extension	Measured Thickness (Depth),	available at the collaborative
CS TS/Ext-Eval	Breslow's Measurement	staging website:
CS Lymph Nodes	CS Site-Specific Factor 2 -	Histologies for Which AJCC
CS Reg Nodes Eval	Ulceration	Staging Is Not Generated
Reg LN Pos	CS Site-Specific Factor 3 -	AJCC Stage
Reg LN Exam	Clinical Status of Lymph Node	Thickness and Ulceration
CS Mets at DX	Mets	Extension and Ulceration
CS Mets Eval	CS Site-Specific Factor 4 - LDH	CS Nodes Pos and Clinical Status
	CS Site-Specific Factor 5	Mets at DX and LDH
	CS Site-Specific Factor 6	

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Tumor Size (Revised: 08/14/2006)

Note: Record the size of the tumor in the CS Tumor Size table below, not depth or thickness. Depth or thickness is recorded in Site-Specific Factor 1 in the Measured Thickness (Depth), Breslow's Measurement table.

Code	Description	
000	No mass/tumor found	
001-988	001 - 988 millimeters (code exact size in millimeters)	
989	989 millimeters or larger	

CS Staging Schemas

990	Microscopic focus or foci only, no size of focus given	
991	Described as "less than 1 cm"	
992	992 Described as "less than 2 cm," or "greater than 1 cm," or "between 1 cm and 2 cm"	
993	Described as "less than 3 cm," or "greater than 2 cm," or "between 2 cm and 3 cm"	
994	Described as "less than 4 cm," or "greater than 3 cm," or "between 3 cm and 4 cm"	
995	Described as "less than 5 cm," or "greater than 4 cm," or "between 4 cm and 5 cm"	
999	Unknown; size not stated Not documented in patient record	

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Extension (Revised: 05/04/2004)

Note 1: If there is a discrepancy between the Clark level and the pathologic description of extent, use the higher (more extensive) code.

Note 2: Satellite lesions/nodules or in-transit metastasis are coded under CS Lymph Nodes.

Note 3: Ulceration of the melanoma is coded in Site-Specific Factor 2.

Code	Description	TNM	SS77	SS2000
00	In situ: noninvasive; intraepidermal Clark's level I Basement membrane of the epidermis is intact	Tis	IS	IS
10	Papillary dermis invaded Clark's level II	*	L	L
20	Papillary-reticular dermal interface invaded Clark's level III	*	L	L
30	Reticular dermis invaded Clark's level IV	*	L	L
40	Skin/dermis, NOS Localized, NOS	*	L	L
50	Subcutaneous tissue invaded (through entire dermis) Clark's level V	*	L	RE
80	Further contiguous extension: Underlying cartilage, bone, skeletal muscle	*	D	D
95	No evidence of primary tumor	TO	U	U
99	Unknown extension Primary tumor cannot be assessed (e.g., shave biopsy or regressed melanoma) Not documented in patient record	*	U	U

* For Extension codes 10 - 80, and 99 ONLY, the T category is assigned based on values the of CS Site-Specific Factor 1, Measured Thickness, and CS Site-Specific Factor 2, Ulceration, as shown in Extra Table 1, Thickness and Ulceration and Extra Table 2, Extension and Ulceration.

CS Staging Schemas

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS TS/Ext-Eval SEE STANDARD TABLE

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Lymph Nodes (Revised: 08/22/2006)

Note 1: Code only regional nodes and nodes, NOS, in this field. Distant nodes are coded in the field Mets at DX. **Note 2:** Satellite lesions/nodules or in-transit metastasis are coded under CS Lymph Nodes.

Note 3: Use codes 10-12 if there is regional node involvement without satellite nodule(s) or in-transit metastases. Use codes 13-15 if there are satellite nodule(s) or in-transit metastases but there is either no regional lymph node involvement, or involvement of regional nodes is not stated. Use codes 20-22 if both satellite nodules(s)/in-transit metastases and regional lymph node(s) are present.

0 Regional lymph nodes by primary site: (includes bilateral or contralateral nodes for head, neck, and trunk) * RN RN HEAD AND NECK SITES: All subsites: Cervical, NOS Lip: Mandibular, NOS: Submandibular(submaxillary) * RN RN	ode Description	TNM	SS77	SS2000
o Regional lymph hodes by primary site. (includes bilateral or contralateral nodes for head, neck, and trunk) HEAD AND NECK SITES: All subsites: Cervical, NOS Lip: Mandibular, NOS: Submandibular(submaxillary)	00 None; no regional lymph node involvement	N0	NONE	NONE
Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Parotid, NOS: Infra-auricular External ear/auditory canal: Mastoid (post-/retro-auricular) (occipital) Preauricular Face, Other (cheek, chin forehead, jaw, nose and temple): Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Parotid, NOS: Submandibular (submaxillary) Parotid, NOS: Infra-auricular Preauricular Scalp: Mastoid (post-/retro-auricular) (occipital) Parotid, NOS: Infra-auricular Preauricular Preauricular Preauricular Preauricular Preauricular Mastoid (post-/retro-auricular) (occipital) Parotid, NOS: Infra-auricular Preauricular	 Regional lymph nodes by primary site: (includes bilateral or contralateral nodes for head, neck, and trunk) HEAD AND NECK SITES: All subsites: Cervical, NOS Lip: Mandibular, NOS: Submandibular(submaxillary) Eyelid/canthus: Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Parotid, NOS: Infra-auricular External ear/auditory canal: Mastoid (post-/retro-auricular) (occipital) Preauricular Face, Other (cheek, chin forehead, jaw, nose and temple): Facial, NOS: Buccinator (buccal) Nasolabial Mastoid (post-/retro-auricular) Parotid, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Pareaticular Face, Other (cheek, chin forehead, jaw, nose and temple): Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Parotid, NOS: Infra-auricular Scalp: Mastoid (post-/retro-auricular) (occipital) Parotid, NOS: Infra-auricular Scalp: Mastoid (post-/retro-auricular) (occipital) Parotid, NOS: Infra-auricular 	*		RN

CS Staging Schemas

		T		<u> </u>
10, cont'd	Preauricular Spinal accessory (posterior cervical) Supraclavicular (transverse cervical) UPPER TRUNK: Axillary Cervical Internal mammary Supraclavicular LOWER TRUNK: Superficial inguinal (femoral) ARM/SHOULDER: Axillary Epitrochlear for hand/forearm Spinal accessory (posterior cervical) for shoulder LEG/HIP: Popliteal for heel and calf Superficial inguinal (femoral) VULVA/PENIS/SCROTUM: Deep inguinal: Rosenmuller or Cloquet node Superficial inguinal (femoral)			
	ALL SITES: Regional lymph node(s), NOS			
12	Regional lymph node(s) by primary site: HEAD AND NECK SITES: Lip: Facial, NOS Buccinator (buccal) Nasolabial Mandibular, NOS Submental Parotid, NOS Infra-auricular Preauricular Eyelid/canthus: Facial, NOS: Mandibular, NOS Submental Face, Other (cheek, chin, forehead, jaw, nose, and temple): Mandibular, NOS Submental Neck: Mandibular, NOS Submental	*	D	RN
13	Satellite nodule(s) or in-transit metastases, NOS (distance from primary tumor not stated) WITHOUT regional lymph node involvement or involvement of regional nodes not stated.	N2c	RE	RE
14	Satellite nodule(s) or in-transit metastases less than or equal to 2cm from primary tumor WITHOUT regional lymph node involvement or involvement of regional nodes not stated.	N2c	RE	RE
15	Satellite nodule(s) or in-transit metastases greater than 2cm from primary tumor WITHOUT regional lymph node involvement or involvement of regional nodes not stated.	N2c	RE	RN

CS Staging Schemas

17	Matted lymph nodes in code 10	N3	RN	RN
18	Matted lymph nodes in code 12	N3	D	RN
20	Satellite nodule(s) or in-transit metastases WITH regional lymph nodes listed in code 10.	N3	RE+RN	RE+RN
22	Satellite nodule(s) or in-transit metastases WITH regional lymph nodes listed in code 12.	N3	D	RE+RN
80	Lymph nodes, NOS	*	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

* For codes 10, 12, and 80 ONLY, the N category depends on the values in Reg LN Pos and SSF 3, as shown in the CS Nodes Pos and Clinical Status table.

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Reg Nodes Eval (Revised: 03/03/2005)

Note: This item reflects the validity of the classification of the item CS Lymph Nodes only according to diagnostic methods employed.

Code	Description	Staging Basis
0	No regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination. Evidence based on physical examination, imaging examination, or other non-invasive clinical evidence. No autopsy evidence used.	с
1	No regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination. Evidence based on endoscopic examination, diagnostic biopsy including fine needle aspiration of lymph node(s), satellite nodule(s) or in-transit metastases (nodules) or other invasive techniques, including surgical observation without biopsy. No autopsy evidence used.	с
2	No regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination, but evidence derived from autopsy (tumor was suspected or diagnosed prior to autopsy).	р
3	Regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination (removal of at least one lymph node, satellite nodule(s) or in-transit metastasis) WITHOUT pre-surgical systemic treatment or radiation OR lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination, unknown if pre-surgical systemic treatment or radiation performed.	р
5	Regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination WITH pre-surgical systemic treatment or radiation, BUT lymph node, satellite nodule(s) or in-transit metastases (nodules) evaluation based on clinical evidence.	с
6	Regional lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination WITH pre-surgical systemic treatment or radiation, and lymph node(s), satellite nodule(s) or in-transit metastases (nodules) evaluation based on pathological evidence.	у
8	Evidence from autopsy; tumor was unsuspected or undiagnosed prior to autopsy.	a

CS Staging Schemas

9	Unknown if lymph nodes, satellite nodule(s) or in-transit metastases (nodules) removed for examination	с
	Not assessed; cannot be assesseed	
	Unknown if assessed	
	Not documented in patient record	

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

Reg LN Pos (Revised: 08/18/2006)

Note 1: Record this field even if there has been preoperative treatment.

Note 2: Although satellite nodules and in-transit metastasis are coded under CS Lymph Nodes, DO NOT count as Reg LN Pos in this field.

Code	Description
00	All nodes examined negative.
01-89	1 - 89 nodes positive (code exact number of nodes positive)
90	90 or more nodes positive
95	Positive aspiration or core biopsy of lymph node(s)
97	Positive nodes - number unspecified
98	No nodes examined
99	Unknown if nodes are positive; not applicable Not documented in patient record

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

Reg LN Exam (Revised: 08/18/2006)

Note: Although satellite nodules and in-transit metastasis are coded under CS Lymph Nodes, DO NOT count as Reg LN Exam in this field.

Code	Description
00	No nodes examined
01-89	1 - 89 nodes examined (code exact number of regional lymph nodes examined)
90	90 or more nodes examined
95	No regional nodes removed, but aspiration or core biopsy of regional nodes performed
96	Regional lymph node removal documented as sampling and number of nodes unknown/not stated
97	Regional lymph node removal documented as dissection and number of nodes unknown/not stated
98	Regional lymph nodes surgically removed but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but number unknown
99	Unknown if nodes were examined; not applicable or negative Not documented in patient record

CS Staging Schemas

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Mets at DX (Revised: 08/22/2006)

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
05	Underlying cartilage, bone, skeletal muscle	*	D	D
10	Distant lymph node(s)	*	D	D
40	Distant metastasis, NOS	*	D	D
42	Metastases to skin or subcutaneous tissue beyond regional lymph nodes	*	D	D
43	Lung	*	D	D
44	All other visceral sites Carcinomatosis Other distant sites	M1c	D	D
52	(10) + (42)	*	D	D
53	(10) + (43)	*	D	D
54	(10) + (44)	M1c	D	D
99	Unknown Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

* For codes 05, 10, 40, 42, 43, 52 and 53 ONLY, the M category is assigned based on the status of serum LDH as coded in Site-Specific Factor 4 LDH table and shown in the Special Mets at DX and LDH table.

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS Mets Eval SEE STANDARD TABLE

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 1 Measured Thickness (Depth), Breslow's Measurement (Revised: 08/15/2006)

Note: Code MEASURED THICKNESS (Depth) of tumor (Breslow's measurement), not size. Record actual measurement in hundredths of millimeters from Pathology Department.

Code	Description
000	No mass/tumor found
001-988	0.01 - 9.88 millimeters Code exact measurement in HUNDREDTHS of millimeters. Examples: 001 0.01 millimeter 002 0.02 millimeters 010 0.1 millimeters 010 0.1 millimeters 100 1 millimeters 105 1.05 millimeters 988 9.88 millimeters
989	9.89 millimeters or larger

CS Staging Schemas

990	OBSOLETE - Microinvasion; microscopic focus or foci only; no size given NOTE: See code 999
999	Microinvasion; microscopic focus or foci only; no size given Not documented in patient record Unknown; size not stated

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Site-Specific Factor 2 Ulceration (Revised: 05/04/2004)

Note 1: Melanoma ulceration is the absence of an intact epidermis overlying the primary melanoma based upon histopathological examination.

Note 2: If there is no documentation or no mention of ulceration in the pathology report, assume ulceration is not present and code 000.

Code	Description
000	No ulceration present
001	Ulceration present
999	Unknown Not stated Not documented in patient record

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 3 Clinical Status of Lymph Node Mets (Revised: 05/04/2004)

Note: Use code 000, No lymph node metastases, if either: A) there is no lymph node involvement, i.e., CS Lymph Nodes is coded 00, or B) there are satellite nodules or in-transit metastases, but no regional lymph node metastases, i.e., CS Lymph Nodes is coded 13-15.

Code	Description
000	No lymph node metastases
001	Clinically occult (microscopic) lymph node metastases only
002	Clinically apparent (macroscopic) lymph node metastases
999	Unknown Not stated Not documented in patient record

Malignant Melanoma of Skin, Vulva, Penis, Scrotum

CS Site-Specific Factor 4 LDH (Revised: 02/04/2005)

Note: Per AJCC, "An elevated serum LDH should be used only when there are 2 or more determinations obtained more than 24 hours apart, because an elevated serum LDH on a single determination can be falsely positive as a result of hemolysis or other factors unrelated to melanoma metastases."

Code	Description
000	Test not done, test was not ordered and was not performed
002	Within normal limits
004	Range 1 less than 1.5 x upper limit of normal for LDH assay; Stated as elevated, NOS

CS Staging Schemas

005	Range 2 1.5 - 10 x upper limit of normal for LDH assay
006	Range 3 more than 10 x upper limit of normal for LDH assay
008	Ordered, but results not in chart
999	Unknown Not stated Not documented in patient record

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Malignant Melanoma of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 6 (Revised: 03/31/2002)

F	Code	Description
	888	Not applicable for this site

This page left blank

Surgery Codes

Skin C440–C449 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[SEER Note: Codes 21 to 24 above combine 20 Local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

[*SEER Notes:* Code UVB phototherapy for mycosis fungoides primaries under Surgery of Primary Site for skin. Assign code 11 if there is no pathology specimen. Assign code 21 if there is a pathology specimen. Codes 20-27 include shave and wedge resection]

- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
 - 31 Shave biopsy followed by a gross excision of the lesion
 - 32 Punch biopsy followed by a gross excision of the lesion
 - 33 Incisional biopsy followed by a gross excision of the lesion
 - 34 Mohs surgery, NOS
 - 35 Mohs with 1-cm margin or less
 - 36 Mohs with more than 1-cm margin

[*SEER Notes:* Codes 30 to 33 include less than a wide excision, less than 1 cm margin or margins are unknown. If it is stated to be a **wide excision** or **reexcision**, but the **margins are unknown**, code to 30. Code 45 represents a wide excision in which it is known that the margins of excision are greater than 1 cm.]

Surgery Codes

- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. Margins MUST be microscopically negative.
 - 46 WITH margins more than 1 cm and less than or equal to 2 cm
 - 47 WITH margins greater than 2 cm

If the excision does not have microscopically negative margins greater than 1 cm, use the appropriate code, 20-36.

- 60 Major amputation
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

Surgery Codes

All Other Sites

C142–C148, C170–C179, C239, C240–C249, C260–C269, C300–C301, C310–C319, C339, C379, C380–C388, C390–C399, C480–C488, **C510–C519**, C529, C570–C579, C589, **C600–C609**, **C630–C639**, C680–C689, C690–C699, C740–C749, C750–C759 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[*SEER Note:* Codes 21 to 24 above combine 20 local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be "debulking"
- 60 Radical surgery

Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs

[*SEER Note:* In continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

This page left blank

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum (M9700-9701) C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2

Note: For Multiple Primary and Histology Coding Rules: see Other Sites (pg C-1079)

This page left blank

CS Staging Schemas

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum (M-9700-9701) C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb and shoulder C44.7 Skin of lower limb and hip C44.8 Overlapping lesion of skin C44.9 Skin, NOS C51.0 Labium majus C51.1 Labium minus C51.2 Clitoris C51.8 Overlapping lesion of vulva C51.9 Vulva, NOS C60.0 Prepuce C60.1 Glans penis C60.2 Body of penis C60.8 Overlapping lesion of penis C60.9 Penis C63.2 Scrotum, NOS Note 1: Laterality must be coded for C44.1-C44.3 and C44.5-C44.7. For codes C44.3 and C44.5, if the tumor is midline (e.g., chin), code as 9 (midline) in the laterality field. Note 2: Source: Developed by the Mycosis Fungoides Cooperative Group (MFCG)

CS Tumor Size	CS Site-Specific Factor 1 -	The following tables are
CS Extension	Peripheral Blood Involvement	available at the collaborative
CS TS/Ext-Eval	CS Site-Specific Factor 2	staging website:
CS Lymph Nodes	CS Site-Specific Factor 3	Histology Exclusion Table
CS Reg Nodes Eval	CS Site-Specific Factor 4	AJCC Stage
Reg LN Pos	CS Site-Specific Factor 5	
Reg LN Exam	CS Site-Specific Factor 6	
CS Mets at DX		
CS Mets Eval		

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Tumor Size SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum

CS Extension (Revised: 08/15/2006)

Note 1: In approximating body surface, the palmar surface of the hand, including digits, is about 1%. **Note 2:** Use code 25 when skin involvement is present but only a general location/site is mentioned (i.e., face, legs, torso, arms). Use code 30 when there is skin involvement but there is no mention of location/site.

Code	Description	TNM	SS77	SS2000
10	Plaques, papules, or erythematous patches ("plaque stage"): Less than 10% of skin surface, no tumors Limited plaques/patches MFCG Stage I	T1	L	L

CS Staging	Schemas
-------------------	---------

20	Plaques, papules, or erythematous patches ("plaque stage"): Greater than or equal to 10% of skin surface, no tumors Generalized plaques/patches MFCG Stage II	T2	L	L
25	Plaques, papules, or erythematous patches ("plaque stage"): % or body surface not stated, no tumors	T2	L	L
30	Skin involvement, NOS: Extent not stated, no tumors Localized, NOS	T1	L	L
50	One or more tumors (tumor stage) Cutaneous tumors	Т3	RE	RE
70	Generalized erythroderma (greater than 50% of body involved with diffuse redness) Sezary syndrome/Sezary disease MFCG Stage III	T4	RE	RE
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS TS/Ext-Eval SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Lymph Nodes (Revised: 08/21/2006)

Note: For this site, code ALL lymph node (regional and distant) involvement in this field.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Clinically enlarged palpable lymph node(s) (adenopathy), and either pathologically negative nodes or no pathological statement	N1	RN	RN
20	No clinically enlarged palpable lymph node(s) (adenopathy); pathologically positive lymph node(s)	N2	RN	RN
30	Both clinically enlarged palpable lymph node(s) (adenopathy) and pathologically positive lymph nodes	N3	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown; not stated Regional lymph node(s) cannot be assessed Not documented in patient record	NX	U	U

CS Staging Schemas

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Reg Nodes Eval SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum Reg LN Pos SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum Reg LN Exam SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Mets at DX (Revised: 08/15/2006)

Note: For this site, code ALL lymph node (regional and distant) involvement in the CS Lymph Nodes field.

Code	Description	TNM	SS77	SS2000
00	No; none	M0	NONE	NONE
40	Visceral (non-cutaneous, extra nodal) involvement: Carcinomatosis Distant metastasis, NOS MFCG Stage IV	M1	D	D
99	Unknown if distant metastasis Distant metastasis cannot be assessed Not documented in patient record	MX	U	U

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Mets Eval SEE STANDARD TABLE

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 1 Peripheral Blood Involvement (Revised: 08/15/2006)

Code	Description
000	No peripheral blood involvement: Less than 1000 Sezary cells
001	Atypical circulating cells in peripheral blood: Less than 5% Greater than or equal to 1000 Sezary cells
002	Atypical circulating cells in peripheral blood: Greater than 5%
003	% not stated
999	Insufficient information Not documented in patient record

CS Staging Schemas

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description	
888	Not applicable for this site	

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum

CS Site-Specific Factor 4 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum

CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum)

CS Site-S	pecific	Factor	6 (Revised:	03/31/2002)
-----------	---------	--------	-------------	-------------

Cod	le	Description
888	8	Not applicable for this site

Surgery Codes

Skin C440–C449 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

00 None; no surgery of primary site; autopsy ONLY

- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser ablation

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[SEER Note: Codes 21 to 24 above combine 20 Local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

[*SEER Notes:* Code UVB phototherapy for mycosis fungoides primaries under Surgery of Primary Site for skin. Assign code 11 if there is no pathology specimen. Assign code 21 if there is a pathology specimen. Codes 20-27 include shave and wedge resection]

- 30 Biopsy of primary tumor followed by a gross excision of the lesion (does not have to be done under the same anesthesia)
 - 31 Shave biopsy followed by a gross excision of the lesion
 - 32 Punch biopsy followed by a gross excision of the lesion
 - 33 Incisional biopsy followed by a gross excision of the lesion
 - 34 Mohs surgery, NOS
 - 35 Mohs with 1-cm margin or less
 - 36 Mohs with more than 1-cm margin

[*SEER Notes:* Codes 30 to 33 include less than a wide excision, less than 1 cm margin or margins are unknown. If it is stated to be a **wide excision** or **reexcision**, but the **margins are unknown**, code to 30. Code 45 represents a wide excision in which it is known that the margins of excision are greater than 1 cm.]

Surgery Codes

- 45 Wide excision or reexcision of lesion or minor (local) amputation with margins more than 1 cm, NOS. Margins MUST be microscopically negative.
 - 46 WITH margins more than 1 cm and less than or equal to 2 cm
 - 47 WITH margins greater than 2 cm

If the excision does not have microscopically negative margins greater than 1 cm, use the appropriate code, 20-36.

- 60 Major amputation
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

Surgery Codes

All Other Sites

C142–C148, C170–C179, C239, C240–C249, C260–C269, C300–C301, C310–C319, C339, C379, C380–C388, C390–C399, C480–C488, **C510–C519**, C529, C570–C579, C589, **C600–C609**, **C630–C639**, C680–C689, C690–C699, C740–C749, C750–C759 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[*SEER Note:* Codes 21 to 24 above combine 20 local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be "debulking"
- 60 Radical surgery

Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs

[*SEER Note:* In continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

This page left blank

Coding Guidelines BONES, JOINTS, AND ARTICULAR CARTILAGE C400–C419 PERIPHERAL NERVES AND AUTONOMIC NERVOUS SYSTEM C470–C479 CONNECTIVE, SUBCUTANEOUS, AND OTHER SOFT TISSUES C490–C499 (Example for M0750, 0760, 0764, 0800, 0820, 0826, 0821, 0020, 0021, 0064, 0080, 0080)

(Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Laterality

Laterality is required for sites C400-C403, C413-C414, C471-C472, and C491-C492.

Three Grade System (Nuclear Grade)

There are several sites for which a three-grade system is used. The patterns of cell growth are measured on a scale of 1, 2, and 3 (also referred to as low, medium, and high grade). This system measures the proportion of cancer cells that are growing and making new cells and how closely they resemble the cells of the host tissue. Thus, it is similar to a four-grade system, but simply divides the spectrum into three rather than four categories (see comparison table below). The expected outcome is more favorable for lower grades. Soft tissue sarcomas are evaluated using a three-grade system.

If a grade is written as 2/3 that means this is a grade 2 of a three-grade system. Do not simply code the numerator. Use the following table to convert the grade to SEER codes.

Term	Grade	SEER Code
1/3, 1/2	Low grade	2
2/3	Intermediate grade	3
3/3, 2/2	High grade	4

Sarcoma

Sarcomas are graded low, intermediate or high grade by the pathologist. Use the following table to convert these terms to a histologic grade.

Term	Grade	SEER Code
Well differentiated	Ι	1
Fairly well differentiated	Π	2
Low grade	I-II	2
Mid differentiated	II	2
Moderately differentiated	II	2
Partially differentiated	Π	2
Partially well differentiated	I-II	2
Partially well differentiated	Π	2
Relatively or generally well differentiated	Π	2
Medium grade, intermediate grade	II-III	3
Moderately poorly differentiated	III	3
Moderately undifferentiated	III	3
Poorly differentiated	III	3
Relatively poorly differentiated	III	3
Relatively undifferentiated	III	3
Slightly differentiated	III	3
High grade	III-IV	4
Undifferentiated, anaplastic, not differentiated	IV	4

Nerves, Nervous System, Soft Tissues C470-479, C490-499

Note: For Multiple Primary and Histology Coding Rules: see Other Sites (pg C-1079)

CS Staging Schemas

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

C47.0-C47.6, C47.8-C47.9, C49.0-C49.6, C49.8-C49.9

C47.0 Peripheral nerves and autonomic nervous system of head, face and neck C47.1 Peripheral nerves and autonomic nervous system of upper limb and shoulder C47.2 Peripheral nerves and autonomic nervous system of lower limb and hip C47.3 Peripheral nerves and autonomic nervous system of thorax C47.4 Peripheral nerves and autonomic nervous system of abdomen C47.5 Peripheral nerves and autonomic nervous system of pelvis C47.6 Peripheral nerves and autonomic nervous system of trunk, NOS C47.8 Overlapping lesion of peripheral nerves and autonomic nervous system C47.9 Autonomic nervous system, NOS C49.0 Connective, subcutaneous and other soft tissues of head, face, and neck C49.1 Connective, subcutaneous and other soft tissues of upper limb and shoulder C49.2 Connective, subcutaneous and other soft tissues of lower limb and hip C49.3 Connective, subcutaneous and other soft tissues of thorax C49.4 Connective, subcutaneous and other soft tissues of abdomen C49.5 Connective, subcutaneous and other soft tissues of pelvis C49.6 Connective, subcutaneous and other soft tissues of trunk C49.8 Overlapping lesion of connective, subcutaneous and other soft tissues C49.9 Connective, subcutaneous and other soft tissues, NOS Note 1: Laterality must be coded for C47.1-C47.2 and C49.1-C49.2. Note 2: Soft tissue sarcomas of the heart and mediastinum (C38.0-C38.3 and C38.9) use the Heart, Mediastinum

schema.

 CS Tumor Size
 C

 CS Extension
 C

 CS TS/Ext-Eval
 C

CS Lymph Nodes

Reg LN Pos

Reg LN Exam

CS Mets at DX

CS Mets Eval

CS Reg Nodes Eval

CS Site-Specific Factor 1 CS Site-Specific Factor 2 CS Site-Specific Factor 3 CS Site-Specific Factor 4 CS Site-Specific Factor 5 CS Site-Specific Factor 6 The following tables are available at the collaborative staging website: Histology Exclusion Table AJCC Stage Special Extension Size Table 1 Special Extension Size Table 2 Special Extension Size Table 3

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues CS Tumor Size SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Extension (Revised: 12/20/2003)

Note 1: Connective tissue includes adipose tissue; aponeuroses; arteries; blood vessels; bursa; connective tissue, NOS; fascia; fatty tissue; fibrous tissue; ligaments; lymphatic channels (not nodes); muscle; skeletal muscle; subcutaneous tissue; synovia; tendons; tendon sheaths; veins; and vessels, NOS. Peripheral nerves and autonomic nervous system includes: ganglia, nerve, parasympathetic nervous system, peripheral nerves, spinal nerves, sympathetic nervous system.

Note 2: If a vessel has a name, for example, brachial artery or recurrent laryngeal nerve, consider it a structure (code 60).

Note 3: For tumors of the extremities and trunk ONLY, superficial lesions are defined as those not involving the superficial muscular fascia. Deep lesions are those that involve or are beneath the superficial fascia.

CS Staging Schemas

Note 4: According to AJCC, "All intraperitoneal visceral lesions, retroperitoneal lesions, and intrathoracic lesions, and the majority of head and neck tumors are considered deep." For coding extension of soft tissue tumors in these sites (C47.0, C47.3-5, C49.0, C49.3-5), use only codes 12, 32, 42, 62, 80, 95, or 99.

Note 5: Definition of Adjacent Connective Tissue: Some of the schemes for ill-defined or non-specific sites in this manual contain a code 40, adjacent connective tissue, which is defined here as the unnamed tissues that immediately surround an organ or structure containing a primary cancer. Use this code when a tumor has invaded past the outer border (capsule, serosa, or other edge) of the primary organ into the organ's surrounding supportive structures but has not invaded into larger structures or adjacent organs. In general, these tissues do not have specific names. These tissues form the framework of many organs, provide support to hold organs in place, bind tissues and organs together, and serve as storage sites for nutrients. Blood, cartilage and bone are sometimes considered connective tissues, but in this manual they are listed separately.

Code	Description	TNM	SS77	SS2000
10	Invasive tumor confined to site/tissue of origin, NOS	***	L	L
11	Superficial invasive tumor confined to site/tissue of origin (lesion does not involve superficial fascia)	*	L	L
12	Deep tumor confined to site/tissue of origin	**	L	L
30	Localized, NOS	***	L	L
31	Superficial: localized tumor, NOS	*	L	L
32	Deep: localized tumor, NOS	**	L	L
40	Adjacent connective tissue (see Note 5)	***	RE	RE
41	Superficial tumor involving adjacent connective tissue	*	RE	RE
42	Deep tumor involving adjacent connective tissue	**	RE	RE
60	Adjacent organs/structures including bone/cartilage (including major vessel invasion) (see Note 5)	***	RE	RE
61	Superficial tumor involving adjacent organs/structures including bone/cartilage (including major vessel invasion) (see Note 5)	*	RE	RE
62	Deep tumor involving adjacent organs/structures including bone/cartilage (including major vessel invasion) (see Note 5)	**	RE	RE
80	Further contiguous extension	**	D	D
95	No evidence of primary tumor	T0	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For Extension codes 11, 31, 41, and 61 ONLY, the T category is assigned based on the value of CS Tumor Size as shown in the Special Extension Size Table 1 for this site.

** For Extension codes 12, 32, 42, 62 and 80 ONLY, the T category is assigned based on the value of CS Tumor Size as shown in the Special Extension Size Table 2 for this site.

*** For Extension codes 10, 30, 40, and 60 ONLY, the T category is assigned based on the value of CS Tumor Size as shown in the Special Extension Size Table 3 for this site.

CS Staging Schemas

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues CS TS/Ext-Eval SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Lymph Nodes (Revised: 08/15/2006)

Note 1: Regional lymph nodes are defined as those in the vicinity of the primary tumor.

Note 2: Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative (code 00). Use code 99 (Unknown) only when there is no available information on the extent of the patient's disease, for example, when a lab-only case is abstracted from a biopsy report and no clinical history is available.

Note 3: For head, neck and trunk primaries ONLY, regional lymph nodes include bilateral or contralateral nodes.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	NO	NONE	NONE
10	Regional lymph nodes by primary site: All Head and Neck Subsites: Cervical Lip: Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Submental	N1	RN	RN
	Parotid, NOS: Infra-auricular Preauricular Eyelid/canthus: Facial, NOS: Buccinator (buccal) Nasolabial Mandibular, NOS: Submandibular (submaxillary) Submental			
	Parotid, NOS: Infra-auricular External ear and auditory canal: Mastoid (posterior, retro-auricular) (occipital) Preauricular Face, Other (cheek, chin, forehead, jaw, nose, and temple): Facial, NOS: Buccinator (buccal) Nasolabial			
	Mandibular, NOS: Submandibular (submaxillary) Submental Parotid, NOS: Infra-auricular Preauricular Scalp: Mastoid (posterior, retro-auricular) (occipital)			

CS Staging Schemas

10,	Parotid, NOS:			
cont'd	Infra-auricular			
	Preauricular			
	Spinal accessory (posterior cervical)			
	Neck:			
	Axillary			
	Mastoid (posterior, retro-auricular) (occipital)			
	Mandibular, NOS			
	Parotid, NOS:			
	Infra-auricular			
	Preauricular			
	Spinal accessory (posterior cervical)			
	Supraclavicular (transverse cervical)			
	Arm/shoulder:			
	Axillary			
	Spinal accessory for shoulder			
	Epitrochlear for hand/forearm			
	Leg/hip:			
	Femoral (superficial inguinal)			
	Popliteal for heel and calf			
	Thorax:			
	Hilar (bronchopulmonary) (proximal lobar) (pulmonary root)			
	Mediastinal			
	Abdomen:			
	Celiac			
	Iliac			
	Para-aortic			
	Pelvis:			
	Deep inguinal, NOS:			
	Rosenmuller or Cloquet node			
	Superficial inguinal (femoral)			
	Upper trunk:			
	Axillary			
	Cervical			
	Internal mammary			
	Supraclavicular (transverse cervical)			
	Lower trunk:			
	Superficial inguinal (femoral)			
	All sites:			
	Regional lymph node(s), NOS			
	Regional Tymph node(3), 1405			
12	Submental nodes for neck primary only (including bilateral or	N1	D	RN
	contralateral)			
15	Neck primary only: (10) + (12)	N1	D	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown (see Note 2)	NX	U	U
99	Unknown (see Note 2)	NX	U	U

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues CS Reg Nodes Eval SEE STANDARD TABLE

CS Staging Schemas

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues Reg LN Pos SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues Reg LN Exam SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues CS Mets at DX SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues CS Mets Eval SEE STANDARD TABLE

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 1 (Revised: 03/27/2003)

Code	Description
888	Not applicable for this site

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 4 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

CS Staging Schemas

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Peripheral Nerves and Autonomic Nervous System; Connective, Subcutaneous, and Other Soft Tissues

CS Site-Specific Factor 6 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Surgery Codes

Bones, Joints, And Articular Cartilage C400–C419 Peripheral Nerves And Autonomic Nervous System C470–C479 Connective, Subcutaneous, And Other Soft Tissues C490–C499 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 19 Local tumor destruction or excision, NOS

Unknown whether a specimen was sent to pathology for surgical events coded 19 (Principally for cases diagnosed prior to January 1, 2003)

15 Local tumor destruction

No specimen sent to pathology from surgical event 15

- 25 Local excision
- 26 Partial resection

Specimen sent to pathology from surgical events 25–26

- 30 Radical excision or resection of lesion WITH limb salvage
- 40 Amputation of limb
 - 41 Partial amputation of limb
 - 42 Total amputation of limb

50 Major amputation, NOS

- 51 Forequarter, including scapula
- 52 Hindquarter, including ilium/hip bone
- 53 Hemipelvectomy, NOS
- 54 Internal hemipelvectomy
- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY

Retroperitoneum, Peritoneum C480-C488

Note: For Multiple Primary and Histology Coding Rules: see Other Sites (pg C-1079)

CS Staging Schemas

CS Site-Specific Factor 6

Extension Size Table

Retroperitoneum and Peritoneum					
C48.0-C48.2, C48.8					
C48.0 Retroperitioneum					
C48.1 Specified parts of peritoneum (inc	cluding omentum and mesentery)				
C48.2 Peritoneum, NOS					
C48.8 Overlapping lesion of retroperitor	neum and peritoneum				
Note: AJCC includes these sites with so	ft tissue sarcomas (C47.0-C48.9)				
CS Tumor Size	CS Site-Specific Factor 1	The following tables are			
CS Extension	CS Site-Specific Factor 2	available at the collaborative			
CS TS/Ext-Eval CS Site-Specific Factor 3 staging website:					
CS Lymph Nodes	CS Site-Specific Factor 4	Histology Exclusion Table			
CS Reg Nodes Eval	CS Site-Specific Factor 5	AJCC Stage			

Retroperitoneum and Peritoneum CS Tumor Size SEE STANDARD TABLE

Retroperitoneum and Peritoneum

CS Extension (Revised: 12/04/2003)

Reg LN Pos

Reg LN Exam CS Mets at DX CS Mets Eval

Note: For AJCC TNM staging, all retroperitoneal lesions are considered deep lesions.

Code	Description	TNM	SS77	SS2000
10	Tumor confined to site of origin	*	L	L
30	Localized, NOS	*	L	L
40	Adjacent connective tissue see definition of adjacent connective tissue in General Instructions.	*	RE	RE
60	Adjacent organs/structures including bone/cartilage Retroperitoneum:Adrenal(s) (suprarenal gland(s))AortaAscending colonDescending colonKidney(s)PancreasVena cavaVertebraPeritoneum:Colon (except ascending and descending colon)EsophagusGallbladderLiverSmall intestineSpleenStomach	*	RE	RE

CS Staging Schemas

80	Further contiguous extension, including: For retroperitoneum, extension to colon other than ascending or descending For peritoneum, extension to ascending or descending colon	*	D	D
95	No evidence of primary tumor	TO	U	U
99	Unknown extension Primary tumor cannot be assessed Not documented in patient record	TX	U	U

* For codes 10-80 ONLY, the T category is assigned based on value of CS Tumor Size, as shown in the Extension Size Table for this site.

Retroperitoneum and Peritoneum CS TS/Ext-Eval SEE STANDARD TABLE

Retroperitoneum and Peritoneum

CS Lymph Nodes (Revised: 12/04/2003)

Note 1: Regional lymph nodes are defined as those in the vicinity of the primary tumor.

Note 2: Regional lymph node involvement is rare. For this schema, if there is no mention of lymph node involvement clinically, assume that lymph nodes are negative (code 00). Use code 99 (Unknown) only when there is no available information on the extent of the patient's disease, for example, when a lab-only case is abstracted from a biopsy report and no clinical history is available.

Code	Description	TNM	SS77	SS2000
00	None; no regional lymph node involvement	N0	NONE	NONE
10	Regional lymph nodes: Intra-abdominal Paracaval Pelvic Subdiaphragmatic Regional lymph nodes, NOS	N1	RN	RN
80	Lymph nodes, NOS	N1	RN	RN
99	Unknown (see Note 2)	NX	U	U

Retroperitoneum and Peritoneum CS Reg Nodes Eval SEE STANDARD TABLE

Retroperitoneum and Peritoneum Reg LN Pos SEE STANDARD TABLE

Retroperitoneum and Peritoneum Reg LN Exam SEE STANDARD TABLE

CS Staging Schemas

Retroperitoneum and Peritoneum CS Mets at DX SEE STANDARD TABLE

Retroperitoneum and Peritoneum CS Mets Eval SEE STANDARD TABLE

Retroperitoneum and Peritoneum CS Site-Specific Factor 1 (Revised: 03/27/2003)

Code	Description
888	Not applicable for this site

Retroperitoneum and Peritoneum

CS Site-Specific Factor 2 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Retroperitoneum and Peritoneum

CS Site-Specific Factor 3 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Retroperitoneum and Peritoneum

CS Site-Specific Factor 4 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Retroperitoneum and Peritoneum

CS Site-Specific Factor 5 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Retroperitoneum and Peritoneum

CS Site-Specific Factor 6 (Revised: 03/31/2002)

Code	Description
888	Not applicable for this site

Surgery Codes

All Other Sites

C142–C148, C170–C179, C239, C240–C249, C260–C269, C300–C301, C310–C319, C339, C379, C380–C388, C390–C399, **C480–C488**, C510–C519, C529, C570–C579, C589, C600–C609, C630–C639, C680–C689, C690–C699, C740–C749, C750–C759 (Except for M9750, 9760-9764, 9800-9820, 9826, 9831-9920, 9931-9964, 9980-9989)

Codes

- 00 None; no surgery of primary site; autopsy ONLY
- 10 Local tumor destruction, NOS
 - 11 Photodynamic therapy (PDT)
 - 12 Electrocautery; fulguration (includes use of hot forceps for tumor destruction)
 - 13 Cryosurgery
 - 14 Laser

No specimen sent to pathology from surgical events 10-14

- 20 Local tumor excision, NOS
 - 26 Polypectomy
 - 27 Excisional biopsy

Any combination of 20 or 26–27 WITH

- 21 Photodynamic therapy (PDT)
- 22 Electrocautery
- 23 Cryosurgery
- 24 Laser ablation

[*SEER Note:* Codes 21 to 24 above combine 20 local tumor excision, 26 Polypectomy or 27 Excisional biopsy with 21 PDT, 22 Electrocautery, 23 Cryosurgery, or 24 Laser ablation]

25 Laser excision

Specimen sent to pathology from surgical events 20–27

- 30 Simple/partial surgical removal of primary site
- 40 Total surgical removal of primary site; enucleation41 Total enucleation (for eye surgery only)
- 50 Surgery stated to be "debulking"
- 60 Radical surgery

Partial or total removal of the primary site WITH a resection in continuity (partial or total removal) with other organs

[*SEER Note:* In continuity with or "en bloc" means that all of the tissues were removed during the same procedure, but not necessarily in a single specimen]

- 90 Surgery, NOS
- 99 Unknown if surgery performed; death certificate ONLY